MX2011011445A - Composiciones que contienen cannabinoides y metodos para su uso. - Google Patents

Composiciones que contienen cannabinoides y metodos para su uso.

Info

Publication number
MX2011011445A
MX2011011445A MX2011011445A MX2011011445A MX2011011445A MX 2011011445 A MX2011011445 A MX 2011011445A MX 2011011445 A MX2011011445 A MX 2011011445A MX 2011011445 A MX2011011445 A MX 2011011445A MX 2011011445 A MX2011011445 A MX 2011011445A
Authority
MX
Mexico
Prior art keywords
cannabinoid
methods
injury
containing compositions
disease condition
Prior art date
Application number
MX2011011445A
Other languages
English (en)
Inventor
Audra Lynn Stinchcomb
Stanley Lee Banks
Original Assignee
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kentucky Res Found filed Critical Univ Kentucky Res Found
Publication of MX2011011445A publication Critical patent/MX2011011445A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Esta invención se refiere a composiciones que contienen cannabinoide, en particular formulaciones de gel que contienen cannabinoide y métodos para el tratamiento de daño traumático, por ejemplo, esguinces, distensiones y contusiones, y condiciones de enfermedad, por ejemplo, artritis, en particular osteoartritis. Los métodos involucran aplicar tópicamente un cannabinoide o una composición que contiene cannabinoide a la piel de un sujeto cerca, o distante de, el área del daño o el área afectada por la condición de enfermedad, por ejemplo, una articulación artrítica. La composición que contiene cannabinoide es de preferencia un gel farmacéuticamente aceptable que contiene una cantidad terapéuticamente efectiva de un cannabinoide suficiente para aliviar los síntomas asociados con el daño o condición de enfermedad.
MX2011011445A 2009-04-29 2009-04-29 Composiciones que contienen cannabinoides y metodos para su uso. MX2011011445A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2009/042124 WO2010126501A1 (en) 2009-04-29 2009-04-29 Cannabinoid-containing compositions and methods for their use

Publications (1)

Publication Number Publication Date
MX2011011445A true MX2011011445A (es) 2011-11-18

Family

ID=41376339

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011445A MX2011011445A (es) 2009-04-29 2009-04-29 Composiciones que contienen cannabinoides y metodos para su uso.

Country Status (6)

Country Link
US (1) US20120202891A1 (es)
EP (1) EP2424568A1 (es)
AU (1) AU2009345154A1 (es)
CA (1) CA2760128A1 (es)
MX (1) MX2011011445A (es)
WO (1) WO2010126501A1 (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2975003B1 (fr) * 2011-05-12 2013-11-01 Jean-Noel Thorel Composition cosmetique topique presentant une penetration amelioree
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US20140113970A1 (en) * 2012-10-22 2014-04-24 Mallinckrodt LLC Covidien Dispensing system
US10265292B2 (en) * 2013-09-18 2019-04-23 The Werc Shop, LLC Terpene-based compositions, processes methodologies
EP3069712B1 (en) * 2013-11-17 2020-09-23 MEDRx Co., Ltd. Transdermal colloidal solution agent
US11660344B2 (en) 2013-11-17 2023-05-30 Medrx Co., Ltd. Transdermal colloidal solution agent
CA2931039C (en) 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US20170224634A1 (en) * 2014-05-29 2017-08-10 Insys Development Company, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
US11541003B1 (en) * 2014-07-28 2023-01-03 Steven Elbogen Compositions, uses and methods for making them
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
AU2016226267A1 (en) 2015-03-02 2017-09-28 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US20170021029A1 (en) * 2015-04-15 2017-01-26 Jeffrey Charles Raber Topical formulations and uses
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US20160374958A1 (en) * 2015-06-23 2016-12-29 Axim Biotechnologies, Inc. Anti-microbial composition comprising cannabinoids
WO2017027553A1 (en) * 2015-08-11 2017-02-16 KannaInnovations LLC Topical compositions comprising hydroxy acids and cannabinoids for skin care
AU2016326518B2 (en) 2015-09-22 2022-03-24 Graphium Biosciences, Inc. Cannabinoid glycoside prodrugs and methods of synthesis
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
CN106074465A (zh) * 2016-06-14 2016-11-09 云南瑞酚生物科技有限公司 大麻酚类化合物在制备治疗痛风性关节炎药物中的应用
CN106074496A (zh) * 2016-06-14 2016-11-09 云南瑞酚生物科技有限公司 大麻酚类化合物在制备治疗痛风药物中的应用
CN106074464A (zh) * 2016-06-14 2016-11-09 云南瑞酚生物科技有限公司 大麻二酚在制备治疗痛风药物中的应用
CN106074493A (zh) * 2016-06-14 2016-11-09 云南瑞酚生物科技有限公司 一种大麻提取物在制备治疗痛风性关节炎药物中的应用
CN106074463A (zh) * 2016-06-14 2016-11-09 云南瑞酚生物科技有限公司 大麻二酚在制备治疗痛风性关节炎药物中的应用
GB2551985B (en) * 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
CN110234228A (zh) * 2016-09-14 2019-09-13 格雷斯培育有限公司 包含非-致病细菌的组合物及保护植物和动物宿主免于真菌、细菌和病毒疾病的方法
US20190255014A1 (en) * 2016-11-07 2019-08-22 Avidas Pharmaceuticals Llc Therapeutic Cannabinoid Formulations and Methods for Their Use
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
WO2018208875A1 (en) * 2017-05-09 2018-11-15 Vitality Biopharma, Inc. Antimicrobial compositions comprising cannabinoids and methods of using the same
US11147777B1 (en) 2017-06-16 2021-10-19 Charlotte's Web, Inc. Methods and formulations for efficacious pain relief by transdermal delivery of cannabidiol
JP7186460B2 (ja) * 2017-08-07 2022-12-09 エナンティア，エセ．エレ． ２－［（１ｒ，６ｒ）－６－イソプロペニル－３－メチルシクロヘキサ－２－エン－１－イル］－５－ペンチルベンゼン－１，３－ジオールの共結晶
BR112020003025A2 (pt) * 2017-08-14 2020-08-04 Zynerba Pharmaceuticals, Inc. métodos de tratamento de osteoartrite com gel transdérmico de canabidiol
US20200289458A1 (en) * 2017-09-22 2020-09-17 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
WO2019118360A1 (en) * 2017-12-11 2019-06-20 Artelo Biosciences, Inc. New solid forms of cannabidiol and uses thereof
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
EP3735225A1 (en) 2018-07-11 2020-11-11 Innocan Pharma Ltd. Pain-relieving topical compositions
US11013715B2 (en) 2018-07-19 2021-05-25 Vertosa, Inc. Nanoemulsion hydrophobic substances
CA3115116A1 (en) * 2018-10-01 2020-04-09 Blue Harvest, Llc Ultrapure phenol compositions
US20220378718A1 (en) 2019-05-28 2022-12-01 Tech Swerve Llc Penetrating topical pain relief compositions and methods of use
EP3975703A4 (en) 2019-05-28 2023-07-12 Tech Swerve LLC PENETRATING TOPICAL PAIN RELIEF COMPOSITIONS AND METHODS OF USE
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
EP3989959A4 (en) * 2019-06-28 2023-05-03 Nexzol Pharma, Inc. TRANSDERMAL FORMULATIONS
US10588871B1 (en) * 2019-06-28 2020-03-17 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
CA3144239A1 (en) * 2019-06-28 2020-12-30 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
JP2022543703A (ja) * 2019-08-09 2022-10-13 ジュピター ウェルネス， インコーポレイテッド Ｃｂｄ製剤およびその使用
US11542243B1 (en) 2019-09-26 2023-01-03 FusionFarms, LLC Method of converting delta9-THC to delta10-THC and the purification of the delta10-THC by crystallization
US11318093B2 (en) * 2019-11-08 2022-05-03 Pac-Dent, Inc. Dental topical anesthetic gel
US20230050379A1 (en) * 2020-01-20 2023-02-16 Nutramax Laboratories, Inc. Novel formulations comprising cannabis
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
JP2023523155A (ja) * 2020-04-20 2023-06-02 パイク セラピューティクス，インコーポレイテッド 慢性疼痛治療のためのカンナビジオール及び／又はテトラヒドロカンナビノールを含有する経皮製剤及び／又は局所製剤
EP4196113A4 (en) * 2020-08-17 2024-04-03 Pike Therapeutics Inc PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
GB202012836D0 (en) * 2020-08-17 2020-09-30 Futura Medical Developments Ltd Topical composition
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
EP4243774A2 (en) * 2020-11-16 2023-09-20 Synergy Life Science, Inc. Cannabinoid emulsifier
US20220202844A1 (en) * 2020-12-31 2022-06-30 Richard Clark Kaufman Drug delivery composition and a method of administering the drug
EP4319730A1 (en) * 2021-04-08 2024-02-14 Pike Therapeutics, Inc. Pharmaceutical composition and method for treating seizure disorders
WO2022219468A1 (en) * 2021-04-12 2022-10-20 Pike Therapeutics, Inc. 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
DK181405B1 (en) 2021-05-25 2023-10-17 Cs Medica As Gel for Intranasal Application, its Provision and Use
WO2023108277A1 (en) * 2021-12-14 2023-06-22 Agile Pharmaceuticals Solutions Inc. Cannabinoid and psychedelic formulations comprising hydrotropic agents
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6113940A (en) * 1997-03-03 2000-09-05 Brooke; Lawrence L. Cannabinoid patch and method for cannabis transdermal delivery
US6132762A (en) * 1997-05-05 2000-10-17 Cristobal; Walter Transcutaneous application of marijuana
US6503532B1 (en) * 2001-04-13 2003-01-07 Murty Pharmaceuticals, Inc. Pharmaceutical composition containing tetrahydrocannabinol and a transdermal/transcutaneous delivery method thereof
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
WO2007030666A2 (en) * 2005-09-07 2007-03-15 Herbal Intervention Corporation Medicated skin care preparation for promoting wound healing
US20080260655A1 (en) * 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses

Also Published As

Publication number Publication date
WO2010126501A1 (en) 2010-11-04
US20120202891A1 (en) 2012-08-09
AU2009345154A1 (en) 2011-12-22
EP2424568A1 (en) 2012-03-07
CA2760128A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
MX2011011445A (es) Composiciones que contienen cannabinoides y metodos para su uso.
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
MX367623B (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
MX2009006543A (es) Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
MX2010003346A (es) Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
MX337575B (es) Compuestos de sulfona y métodos para lafabricación y uso de éstos.
WO2008086014A3 (en) Bis-aryl amide derivatives useful for the treatment of cancer
MX2009008531A (es) Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
GB2511685A (en) Muscarinic m1 receptor agonists
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
ZA201108305B (en) Novel p2x7r antagonists and their use
WO2011038933A3 (en) Anti-hsv antibody
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
WO2007135026A3 (de) Substituierte pteridine als therapeutika
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
MY150931A (en) Substituted oxazolidinones and their use
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
UA112420C2 (uk) Інгібітори апоптозу та їх застосування
MX2013002119A (es) Sustituidas-2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas como moduladores de kcnq2/3.
WO2011060253A3 (en) Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms

Legal Events

Date Code Title Description
FA Abandonment or withdrawal